Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04103060Phase 2Completed

Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

Role: lead

NCT02950922Phase 2Completed

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

Role: lead

NCT03394677Phase 2Completed

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

Role: lead

NCT03415282Phase 1Unknown

Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

Role: lead

All 4 trials loaded